Department of Immunobiology, Yale University, New Haven, Connecticut 06520, USA.
Nat Rev Immunol. 2013 Apr;13(4):243-56. doi: 10.1038/nri3422.
Type 1 diabetes (T1D) remains an important health problem, particularly in western countries, where the incidence has been increasing in younger children. In 1986, Eisenbarth described T1D as a chronic autoimmune disease. Work over the past three-and-a-half decades has identified many of the genetic, immunological and environmental factors that are involved in the disease and have led to hypotheses concerning its pathogenesis. Clinical trials have been conducted to test these hypotheses but have had mixed results. Here, we discuss the findings that have led to our current concepts of the disease mechanisms involved in T1D and the clinical studies promoted by these studies. The findings from preclinical and clinical studies support the original proposed model for how T1D develops but have also suggested that this disease is more complex than was originally thought and will require broader treatment approaches.
1 型糖尿病(T1D)仍然是一个重要的健康问题,特别是在西方国家,那里的发病率在年幼的儿童中一直在增加。1986 年,Eisenbarth 将 T1D 描述为一种慢性自身免疫性疾病。过去三十五年的研究已经确定了许多与该疾病相关的遗传、免疫和环境因素,并提出了关于其发病机制的假设。已经进行了临床试验来检验这些假设,但结果喜忧参半。在这里,我们讨论了导致我们目前对 T1D 相关疾病机制的概念的发现,以及这些研究促进的临床研究。临床前和临床研究的结果支持了最初提出的 T1D 发展模型,但也表明这种疾病比最初想象的更为复杂,需要更广泛的治疗方法。